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Background: Thymic carcinomas are rare cancers with limited data 
regarding outcomes, particularly for those patients with advanced 
disease.
Methods: We identified patients with thymic carcinomas diagnosed 
between 1993 and 2012. Patient characteristics, recurrence-free sur-
vival (RFS), and overall survival (OS) were analyzed.
Results: One hundred twenty-one patients with thymic carcinomas 
were identified. Higher Masaoka stage was associated with worse 
OS and RFS (5-year OS of 100%, 81%, 51%, 24%, and 17% for 
stage I, II, III, IVa, and IVb respectively, p < 0.001 and 5-year RFS of 
80%, 28%, and 7% for stage I/II, III, and IV respectively, p < 0.001). 
Patients with stage IVb lymph node (LN) only disease had a better 
5-year OS as compared with patients with distant metastasis (24% 
versus 7%, p = 0.025). Of the 61 patients with stage IVb disease, 
22 of 29 patients (76%) with LN-only disease underwent curative 
intent resection versus 3 of 32 patients (9%) with distant metastasis. 
Twenty-two patients with LN involvement were treated with multi-
modality therapy. Three (14%) remain free of disease with long-term 
follow-up (range, 3.4+ years– to 6.8+ years).
Conclusions: We describe the clinical features of a large series of 
patients with thymic carcinoma in North America. The Masaoka 
staging system effectively prognosticated OS and RFS. Patients with 
stage IVb LN-only disease had significantly better OS as compared 
with patients with distant metastasis with a subset of patients sustain-
ing long-term RFS with multimodality therapy. If validated, these 
data would support a revised staging system with subclassification of 
stage IVb disease into two groups.
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(J Thorac Oncol. 2014;9: 1810–1815)
Thymic carcinomas are rare tumors, representing only 15% to 20% of all thymic neoplasms with fewer than 500 cases 
diagnosed in the United States per year.1,2 As such, most of 
the literature on thymic carcinomas comes from retrospec-
tive reviews of surgical series, often from countries in Asia, 
where thymic carcinoma appears to be more prevalent.3–16 
Data is limited regarding the clinical characteristics and clini-
cal behavior in a Western population, particularly in patients 
with advanced disease who are not surgical candidates.
Because of the rarity of the disease and absence of pro-
spective data, there is no overall consensus about the ideal 
staging system for thymic carcinomas. The Masaoka staging 
system is widely used to stage thymomas as it can predict for 
overall survival (OS) in this disease. However, several groups 
have reported that similar results are not seen in thymic car-
cinomas.6,13,15,17–19 These authors evaluated mostly small surgi-
cal series and showed that survival differences were observed 
only when comparing early versus advanced Masaoka stage 
or when other anatomical factors, such as involvement of 
the great vessels, were taken into account.6,18–21 Ruffini et 
al.22 recently showed good prognostic stratification among 
Masaoka staging, although stages I and II were again grouped 
together because of a similar survival. A tumor, node, metasta-
sis (TNM) based staging system has been proposed for thymic 
carcinomas—however this staging system has thus far failed 
to show significant survival differences in several studies.23,24
In this study, we describe our experience in the manage-
ment of 121 surgical and nonsurgical cases of thymic carci-
nomas evaluated at Memorial Sloan Kettering Cancer Center 
over a 20 year period. The aim of this study was to describe the 
clinical characteristics of patients with thymic carcinoma and 
to identify prognostic factors of survival. Based on a prere-
view of our institutional experience, we hypothesized that the 
Masaoka staging system can effectively prognosticate overall 
and recurrence-free survival and that those patients with stage 
IVb lymph node only disease would have longer survival as 
compared with patients with distant metastasis.
PATIENTS AND METHODS
Patient Selection
We identified all consecutive patients diagnosed with 
thymic carcinoma between January 1, 1993 and December 31, 
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2012 at Memorial Sloan Kettering Cancer Center (MSKCC). 
Patients with thymomas, well differentiated thymic carcino-
mas (type B3 thymomas), thymic carcinoid tumors, or thy-
mic small- or large-cell neuroendocrine carcinomas were 
excluded from this analysis. This cohort of patients includes 
the 23 patients described by Huang et al.9 and Bott et al.25 All 
pathology specimens were reviewed at MSKCC to confirm 
the diagnosis. Approval for this retrospective chart review was 
obtained from the institutional review board at MSKCC.
Data Collection
Patient characteristics and outcomes including age, race, 
sex, smoking history, evidence of paraneoplastic syndromes, 
stage, treatment details including use of chemotherapy, sur-
gery, and/or radiation, recurrence data, and the last date of 
follow-up/date of death were abstracted from medical records 
manually and analyzed retrospectively. Preoperative imaging 
was regularly performed with a computed tomography scan 
of the chest, abdomen, and pelvis. The staging was character-
ized according to Masaoka staging.26 Total thymectomy, with 
or without en bloc resection of adjacent structures performed 
through a median sternotomy, was the standard procedure for 
resection of thymic carcinoma during the study period. The 
lymph nodes were staged using N0 and N1 categories as exten-
sive nodal dissections were not routinely performed in a sys-
tematic manner. Resection status was evaluated using operative 
and pathology reports. Resection status was characterized as 
R0 if all the margins were microscopically negative, R1 if the 
margins were microscopically positive, or R2 if grossly incom-
plete resection was performed. Follow-up status was obtained 
from institutional records and verified by the Social Security 
Death Index. Recurrence was defined as clinical appearance of 
new disease by imaging and/or pathology after curative intent 
resection. Type of recurrence, either local (mediastinal), intra-
thoracic (lung/pleura), or distal (extrathoracic) was recorded.
Statistical Analysis
Two endpoints were investigated: OS in the full cohort 
and time to recurrence in the subset of patients who had a 
curative intent surgery. Both the endpoints were estimated 
by the Kaplan-Meier method, and univariate associations 
between patient, disease or treatment factors and survival 
were analyzed using the log-rank test. OS was defined as 
the time from pathologic diagnosis until death by any cause. 
The time to recurrence was defined as the time from surgical 
resection until the date of imaging confirming recurrence of 
disease. In each analysis, patients who did not experience the 
event of interest during the study time were censored at the 
date of the last available follow-up. All statistical tests were 
two-sided and used a 5% significance level. Statistical analy-
ses were performed using R (version 3.0.1; R Development 
Core Team, R Foundation for Statistical Computing, Vienna, 
Austria), including the “survival” and “survcomp” packages.
RESulTS
Patient Characteristics
One hundred twenty-one patients were diagnosed with 
thymic carcinoma during the study period. Patient characteristics 
are summarized in Table 1. The majority of patients with thy-
mic carcinoma presented with locally advanced (III, IVa) or 
metastatic disease at diagnosis, with squamous cell carcinoma 
as the most common histologic subtype. Three patients devel-
oped concurrent dermatomyositis and one patient developed 
limbic encephalitis with positive anti-voltage-gated potassium 
channel antibodies during their clinical course. Myasthenia 
gravis was not seen in any patients. On univariate analyses, 
age, sex, smoking history, and the presence of a paraneoplastic 
syndrome were not associated with OS.
OS by Stage
Stage at initial diagnosis was associated with OS 
(p < 0.001, Fig. 1). Five-year OS was 100%, 81%, 51%, 24%, 
and 17% for stage I, II, III, IVa, and IVb, respectively.
OS Based on Type of Resection
Of the 121 patients analyzed, 77 patients underwent 
resection with curative intent. Two patients had surgical 
TABlE 1.  Patient Demographics (n = 121)
Age at Diagnosis (years) 58 (12–84)
Women 52 (43%)
Race
  White 91 (75%)
  Asian 14 (12%)
  Black 11 (9%)
  Hispanic 3 (2%)
  Other 2 (2%)
Smoking status
  Never smokers 74 (61%)
  Light smokers (≤15 pack years) 16 (13%)
  Heavy smokers (>15 pack years) 31 (26%)
Masaoka stage at diagnosis
  Stage I 7 (6%)
  Stage II 13 (11%)
  Stage III 25 (21%)
  Stage IVa 13 (11%)
  Stage IVb 61(50%)
  Undeterminate stage 2 (2%)
Paraneoplastic syndrome
  Dermatomyositis 3 (3%)
  Anti-voltage-gated potassium channel  
antibodies
1 (1%)
  Myasthenia gravis 0 (0%)
Histologic subtype
  Squamous cell carcinoma 65 (54%)
  Undifferentiated carcinoma 32 (27%)
  Lymphoepithelioma-like carcinoma 9 (7%)
  Basaloid carcinoma 7 (6%)
  Mucoepidermoid carcinoma 1 (1%)
  Sarcomatoid carcinoma 1 (1%)
  Clear cell carcinoma 2 (2%)
  Carcinoma with neuroendocrine 
features
4 (3%)
C- kit mutation 3/19 (16%)
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resections outside of MSKCC and the details of the resec-
tion could not be assessed. Complete tumor resection with 
pathologically confirmed negative resection margins (R0) was 
achieved in 35 (47%) patients. Twenty-two (29%) patients had 
microscopic residual disease (R1), and 18 (24%) patients had 
gross residual disease (R2). 48% of the patients with an R0 
resection underwent adjuvant mediastinal radiation as com-
pared with 94% and 88% for R1 and R2 resections, respec-
tively. OS was significantly improved for patients who had a 
R0 or R1 resection versus a R2 resection (p = 0.018, Fig. 2). 
For R0, R1, and R2 resection, the 5-year OS was 60%, 49%, 
and 32%, respectively.
OS Based on Distant Metastasis Versus 
lymph Node Only Involvement
Sixty-one patients were diagnosed with stage IVb 
disease at initial diagnosis. Twenty-nine patients had lymph 
node involvement without distant metastasis. Of the 29 
patients, 14 patients had preoperative findings of enlarged 
lymph nodes by imaging and 15 patients were diagnosed 
with positive lymph nodes after pathology review of the 
resected specimen. Thirty-two patients had distant meta-
static disease (69% had lung metastasis, 41% had bone 
metastasis, and 31% of the patients had liver metastasis 
involvement at presentation). Of the 61 patients with stage 
IVb disease, 22 of 29 patients (76%) with lymph node only 
involvement underwent resection as compared with 3 of 32 
patients (9%) with distant metastasis (p < 0.001). Stage IVb 
patients with lymph node involvement had a better 5-year 
OS as compared with patients with distant metastasis (24% 
versus 7%, p = 0.025, Fig. 3).Management of Early Stage 
Disease.
Our series included seven patients with stage I disease 
and 13 patients with stage II disease. All the patients with 
stage I and stage II disease were treated with resection. All the 
patients with stage I disease had an R0 resection as compared 
with 69% of the patients with stage II disease. None of the 
stage I patients received additional perioperative chemother-
apy or radiation therapy. Nine of the 13 patients with stage II 
disease received adjuvant mediastinal radiation, including all 
patients with a R1 resection. Five-year OS was 100% and 81% 
for stage I and II disease, respectively.
FIGuRE 1.  Overall survival based on 
stage at diagnosis.
FIGuRE 2.  Overall survival based on type 
of resection.
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Management of locally Advanced, 
Resectable Disease and Role of 
Neoadjuvant Chemotherapy
We assessed outcomes in locally advanced disease, 
including all stage III patients and selected patients with stage 
IVa–IVb disease with intrathoracic involvement that were 
treated with curative intent resection. This included a total of 
54 patients. Thirty-seven patients received neoadjuvant che-
motherapy before surgery, whereas 17 patients received initial 
surgery. Of the 37 patients who received neoadjuvant chemo-
therapy, 39% of these patients had a R0 resection as compared 
with 21% of the patients with upfront surgery (p = 0.095). Most 
neoadjuvant chemotherapy administered was platinum based.
Management of unresectable locally 
Advanced or Metastatic Disease
Forty-four patients including four patients with stage III 
disease, three patients with stage IVa disease, and 37 patients 
with stage IVb disease were felt to be unresectable. Of these 
44 patients, 13 received chemoradiation, 20 received pallia-
tive chemotherapy, two received palliative radiation and nine 
were lost to follow-up and/or received no further treatment. 
The median OS for these patients was 19 months (95% confi-
dence interval [CI], 15–31).
Recurrence
Of the 74 evaluable patients who had potentially cura-
tive resection and recurrence data available, 40 patients (53%) 
had recurrence or disease progression. The stage at initial 
diagnosis was significantly associated with the rate of recur-
rence (p < 0.001, Fig. 4). Four of the 20 patients (20%) with 
initial stage I/II disease recurred as compared with 36 of the 
54 patients (67%) with locally advanced disease (stage III, 
IVa, or IVb disease). The median time to recurrence was 11 
months (range, 2–108 months). In the mediastinum 13% of 
the patients recurred, 48% of the patients recurred in the tho-
rax (pleura and lung), and 39% recurred distally. The distant 
sites included lung, bone, and liver. Brain metastases were 
identified in two patients.
Multimodality Therapy in Stage IVb 
Disease with lymph Node Involvement
Twenty-two patients with stage IVb disease received 
multimodal therapy including curative-intent resection, medi-
astinal radiation, and/or chemotherapy. Thirteen of these 22 
patients received neoadjuvant chemotherapy with postoperative 
mediastinal radiation, six received adjuvant chemotherapy and 
postoperative mediastinal radiation, and three patients received 
postoperative mediastinal radiation without chemotherapy. Of 
these patients, 3 of 22 (14%) are currently free of disease with 
long-term follow-up (Table 2). One patient had a local recur-
rence 16 months after definitive resection, had the recurrence 
resected, and has been free of disease for over 4.9 years.
DISCuSSION
Our study represents one of the largest reported series 
of patients with localized and advanced, unresectable disease 
treated in North America. The results of our study indicate 
several important findings: (1) The Masaoka staging system 
predicts likelihood of overall and recurrence-free survival; (2) 
patients with stage IVb lymph node-only disease have a better 
OS as compared with patients with distant metastasis; and (3) 
for a subset of patients with stage IVb lymph node only disease, 
treatment with multimodality therapy including surgery, chemo-
therapy, and radiation can result in a long-term recurrence-free 
survival. These data should prompt consideration of a revised 
Masaoka staging system with subclassification of stage IVb 
disease into two groups if supported by data in the International 
Thymic Malignancies Interest Group staging database.
For patients who undergo surgical resection, our data 
support the importance of an R0 resection. Specifically, we 
showed that a R0 or R1 resection is associated with improved 
OS, as compared with an R2 debulking procedure. The similar 
survival curves for R0 and R1 resections could be explained 
FIGuRE 3.  Overall survival for patients with 
stage IVb disease based on metastatic site.
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by the fact that most patients with a R1 resection received 
adjuvant radiation therapy.
For patients with advanced disease, a multidisciplinary 
approach, including the collaboration of radiation oncologists, 
medical oncologists, oncologic surgeons, pathologists, and 
radiologists may be considered in the comprehensive manage-
ment of these complicated patients. We showed that platinum-
based neoadjuvant chemotherapy can potentially improve the 
rates of R0 resection, although a randomized clinical trial 
would need to be performed to confirm these results.
Finally, our results demonstrate that myasthenia gravis 
is an incredibly rare event in thymic carcinoma. Although 
myasthenia gravis is diagnosed in up to 50% of the patients 
with thymomas, this autoimmune paraneoplastic disorder was 
not detected in any of the 121 patients with thymic carcinomas 
evaluated.27 Others report that patients with thymic carcinoma 
can present with myasthenia gravis.3,7,22 However, we believe 
that when this autoimmune phenomenon is present, the diag-
nosis of thymic carcinoma needs to be reconfirmed and thy-
moma ruled out.
Our study has several strengths and limitations. The 
main strength of this study is that it represents one of the larg-
est series of patients with localized and advanced, unresectable 
disease treated in North America. Furthermore, all biopsies 
and surgical specimens obtained were reviewed by expert 
pathologists in one center. It is well known that there is sig-
nificant interobserver variation in the classification of thymic 
tumors making central pathology review essential for accu-
racy.28 In addition, patients with thymomas and well differen-
tiated thymic carcinomas (B3 thymomas) were excluded from 
the analysis. Many studies have grouped thymic carcinomas 
and thymomas in the same analysis based on past histologic 
classifications. However, the latest World Health Organization 
histologic classification observes that thymic carcinomas are 
a distinct group of thymic malignancies and recommends 
that they be analyzed separately.29 Finally, as data was col-
lected from one center, information regarding clinical char-
acteristics, recurrences, resection status, and chemotherapy 
responses were readily available for most patients. As with 
previously reported reviews of thymic carcinoma, our study is 
limited by the retrospective nature of the data collection and 
heterogeneity of treatments. Furthermore, our median follow-
up time was 24 months, and a longer follow-up may provide 
more data regarding late recurrences.
In conclusion, our results demonstrate that the Masaoka 
staging system can prognosticate overall and recurrence-free 
FIGuRE 4.  Recurrence-free survival based 
on stage.
TABlE 2.  Individual Patient Characteristics of the Stage IVb Patients Who Are Currently NED
Patient
Age  
(years) Sex
Pack  
(years) Race Histology Type
Masaoka
Stage
at Diagnosis Treatment
Areas of  
Metastasis Recurrence
Disease-Free  
Survival
since resection
1 36 F 12 Asian Squamous IVb Resection/XRT/
neoadjuvant 
chemotherapy
Lymph node
(no visceral 
metastasis)
No 6.8 years+
2 43 F 0.6 White Lympho-epithelioma-
like carcinoma
IVb Resection/XRT/
neoadjuvant 
chemotherapy
Lymph node
(no visceral 
metastasis)
No 3.4 years+
3 82 M 0 White Lympho-eptihelioma-
like carcinoma
IVb Resection/XRT/
neoadjuvant 
chemotherapy
Lymph node 
(no visceral 
metastasis)
Yes: local recurrence
to mediastinum.
Pt treated with resection.
4.9 years+
F, female; M, male; NED, no evidence of disease; Pt, patient; XRT, external beam radiation therapy.
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survival. Our data suggests that patients with stage IVb lymph 
node disease may have a better OS as compared with patients 
with distant metastasis and can achieve long-term disease-free 
survival with multimodality therapy. The rates of recurrence 
are high at all stages of the disease, with distant disease in the 
liver, bone, and lungs usually seen. Thus, prospective trials and 
collaborative efforts are necessary in the future to evaluate and 
compare therapies to improve outcomes in this rare disease.
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